期刊
EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM
卷 17, 期 2, 页码 167-178出版社
ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
DOI: 10.1080/17446651.2022.2060819
关键词
Thyroid cancer; RET fusion; molecular pathology; selpercatinib; pralsetinib
This review summarizes the biological and predictive role of RET gene fusions in thyroid cancer, as well as the latest screening assays for detecting these genomic alterations. Next-generation sequencing for detecting RET fusions has become a commonly used strategy in clinical practice for selecting the best treatment options.
Background: Rearranged during transfection (RET) gene fusions are detected in 10-20% of thyroid cancer patients. Recently, RET fusion-positive metastatic thyroid cancers have attracted much attention owing to the FDA approval of two highly selective anti-RET tyrosine kinase inhibitors, namely, selpercatinib, and pralsetinib. Areas covered: This review summarizes the available evidence on the biological and predictive role of RET gene fusions in thyroid carcinoma patients and the latest screening assays currently used to detect these genomic alterations in histological and cytological specimens. Expert opinion: Management of advanced thyroid carcinoma has significantly evolved over the last decade thanks to the approval of three multikinase inhibitors, i.e. sorafenib, lenvatinib, cabozantinib, and of two selective RET-tyrosine inhibitors, i.e. selpercatinib and pralsetinib. In this setting, the detection of RET-fusions in advanced thyroid cancer specimens through the use of next-generation sequencing has become a commonly used strategy in clinical practice to select the best treatment options.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据